Our Q2 Hedge Fund data is now updated! A few favorite stocks are lining up for major readouts in Q3–Q4, and some are likely to move big. Below are 6 key catalysts we’re watching closely. 📈 📉   $ MLTX  Sonelokimab / Hidradenitis Suppurativa / Phase 3 » Potential for a highly differentiated, “gold standard” therapy in HS » Achieved highest responses to date in HS » Ph2 MIRA trial in HS was designed as a pivotal study Ph2 results recap 👇 $ CRNX  Paltusotine / Acromegaly / PDU

Our Q2 Hedge Fund data is now updated! A few favorite stocks are lining up for major readouts in Q3–Q4, and some are likely to move big.

If you are looking for another interesting company to diligence, check out COGT. They are trying to develop a therapeutic that would compete with BPMC's lead drug AYVAKIT® (avapritinib) to treat Systemic Mastocytosis (SM). BPMC announced yesterday that it agreed to be acquired by SNY for ~$9B, whereas COGT has a current market cap around $650M and EV ~$500M. Thus, if COGT were successful to develop a therapeutic to displace AYVAKIT, investors would be handsomely rewarded. COG

This weekend COGT reports some Big-Mover data on  Bezuclastinib (CGT9486) at ASH. COGT Clinical Pipelilne COGT is a biopharma hedge-fund favorite. In fact, as of Sep 30, 2023, they were held by 15 of the top 34 biopharma hedge funds that we track. That is more than any other company. And they remain one of the most popular Top 20 holdings in those funds. COGT's lead asset, Bezuclastinib (CGT9486), is a KIT inhibitor that is being developed to treat GIST and Systemic Mastocyto

This weekend COGT reports some Big-Mover data on  Bezuclastinib (CGT9486) at ASH.

Summary:

Article currently in progress (1/17/23) Summary: ASCO-GI starts this Thursday, January 19, 2023 This conference focuses on indications including stomach cancer, gastrointestinal cancer, esophageal cancer, and colorectal cancer ( https://conferences.asco.org/gi/program ) In past years, big readouts have happened at this conference including from several Phase 3 trials On Thursday Jan 19 there is also a PDUFA for a GI indication: the SGEN and MRK PDUFA for Tukysa (Tucatinib) to

$XBI $63.42 | +0.16% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates # Pipeline Updates #OTLK +16%...

$XBI $63.42 | +0.16% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates # Pipeline Updates #OTLK +16%...

$XBI $63.32 | -5.53% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX -10.7% Novavax COVID-19...

$XBI $63.32 | -5.53% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX -10.7% Novavax COVID-19...

$XBI $67.03 | -4.60% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #GRTS -0.4% Gritstone Announces...

$XBI $67.03 | -4.60% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #GRTS -0.4% Gritstone Announces...

As we begin June, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for...